作者
Ruth E Farmer, Ivan Beard, Syed I Raza, Nicholas D Gollop, Niraj Patel, Abigail Tebboth, Andrew P McGovern, Naresh Kanumilli, Andrew Ternouth
发表日期
2021/2/1
期刊
Clinical Therapeutics
卷号
43
期号
2
页码范围
320-335
出版商
Elsevier
简介
Purpose
Some classes of glucose-lowering medications, including sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1-receptor agonists (GLP1-RAs) have cardio-protective benefit, but it is unclear whether this influences prescribing in the United Kingdom (UK). This study aims to describe class-level prescribing in adults with type 2 diabetes mellitus (T2DM) by cardiovascular disease (CVD) history using the Clinical Practice Research Datalink (CPRD).
Methods
Four cross-sections of people with T2DM aged 18–90 and registered with their general practice for >1 year on 1st January 2017 (n = 166,012), 1st January 2018 (n = 155,290), 1st January 2019 (n = 152,602) and 31st December 2019 (n = 143,373) were identified. Age-standardised proportions for class use through time were calculated separately in those with and without CVD history and by total number of medications …
学术搜索中的文章
RE Farmer, I Beard, SI Raza, ND Gollop, N Patel… - Clinical Therapeutics, 2021